Abstract
In a recent patent, Wanebo HJ proposed to increase “apoptosis in a cancer cell comprising contacting the cancer cell with (a) oxaliplatin and (b) C6-ceramide, sequentially or concomitantly”. Cisplatin and derivatives are commonly used in the treatment of solid tumors. Cisplatin induces DNA adducts, which are responsible for the induction of a cellular stress, leading to the elimination of the proliferating cells by apoptosis. Recently, a different mechanism has been reported to explain the tumoricidal action of platinum-based agents. Indeed, cells treated with cisplatin exhibit an increase in plasma membrane fluidity through the activation of acid sphingomyelinase, the subsequent generation of ceramide and the redistribution of the death receptor CD95 into the lipid rafts. This latter event promotes the initiation of the apoptotic signal and the elimination of the malignant cells. In this review, we discuss the potential role played by the death receptor in the potentiation effect of exogenously added ceramide upon the oxaliplatin-mediated cytotoxic effect.
Keywords: CD95, apoptosis, ceramide, sphingomyelinase, tumor, chemoresistance, cisplatin, lipid rafts
Recent Patents on Anti-Cancer Drug Discovery
Title: Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?
Volume: 5 Issue: 1
Author(s): Bruno Segui and Patrick Legembre
Affiliation:
Keywords: CD95, apoptosis, ceramide, sphingomyelinase, tumor, chemoresistance, cisplatin, lipid rafts
Abstract: In a recent patent, Wanebo HJ proposed to increase “apoptosis in a cancer cell comprising contacting the cancer cell with (a) oxaliplatin and (b) C6-ceramide, sequentially or concomitantly”. Cisplatin and derivatives are commonly used in the treatment of solid tumors. Cisplatin induces DNA adducts, which are responsible for the induction of a cellular stress, leading to the elimination of the proliferating cells by apoptosis. Recently, a different mechanism has been reported to explain the tumoricidal action of platinum-based agents. Indeed, cells treated with cisplatin exhibit an increase in plasma membrane fluidity through the activation of acid sphingomyelinase, the subsequent generation of ceramide and the redistribution of the death receptor CD95 into the lipid rafts. This latter event promotes the initiation of the apoptotic signal and the elimination of the malignant cells. In this review, we discuss the potential role played by the death receptor in the potentiation effect of exogenously added ceramide upon the oxaliplatin-mediated cytotoxic effect.
Export Options
About this article
Cite this article as:
Segui Bruno and Legembre Patrick, Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (1) . https://dx.doi.org/10.2174/157489210789702190
DOI https://dx.doi.org/10.2174/157489210789702190 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Meet Our Associate Editorial Board Member
Current Pharmaceutical Biotechnology New Therapeutic Strategies for Castration-Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Immune Receptors, Cadherins and their Interactions
Current Immunology Reviews (Discontinued) On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy Hedgehog Signaling and Urological Cancers
Current Drug Targets Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Effect of Verbascum thapsus Ethanol Extract on Induction of Apoptosis in <i>Trichomonas vaginalis in vitro</i>
Infectious Disorders - Drug Targets Macrocyclic Inhibitors of Hsp90
Current Topics in Medicinal Chemistry Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Current Medicinal Chemistry Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Psychological Treatments for Hypochondriasis: A Narrative Review
Current Psychiatry Reviews A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism Emerging Immunotargets in Bladder Cancer
Current Drug Targets Genome Analysis of Food Grade Lactic Acid-Producing Bacteria: From Basics to Applications
Current Genomics Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Improving Health Care for Children with Chronic Conditions: Toward a “Wholistic” Approach
Current Pediatric Reviews Dimethyl Sulfoxide as an Excitatory Modulator and its Possible Role in Cancer Pain Management
Inflammation & Allergy - Drug Targets (Discontinued) Analgesic and Antineuropathic Drugs Acting Through Central Cholinergic Mechanisms
Recent Patents on CNS Drug Discovery (Discontinued) Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors
Recent Patents on Anti-Cancer Drug Discovery